sellWeak cluster of 710b5-1 plan
Suresh K. Durgam sold $673k of ITCI
EVP, Chief Medical Officer at Intra-Cellular Therapies, Inc.. 10,162 shares at an average of $66.21, traded Mar 7, 2024, filed Mar 11, 2024.
Warning score
25Value
$673k
10,162 shares
Holdings after
19,803
-45% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +20Trade size$673k at market
- +10Share of holdings soldSold 45% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-029578, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 7, 2024 | SOpen-market sale Common Stock10b5-1 | -3,728 | $66.34 | $247k | 18,892 | Mar 11, 2024 |
| Mar 7, 2024 | SOpen-market sale Common Stock10b5-1 | -2,722 | $66.86 | $182k | 16,170 | Mar 11, 2024 |
| Mar 10, 2024 | MOption exercise Common Stock10b5-1 | +7,345 | - | - | 23,515 | Mar 11, 2024 |
| Mar 11, 2024 | SOpen-market sale Common Stock10b5-1 | -2,179 | $65.06 | $142k | 21,336 | Mar 11, 2024 |
| Mar 11, 2024 | SOpen-market sale Common Stock10b5-1 | -872 | $65.89 | $57k | 20,464 | Mar 11, 2024 |
| Mar 11, 2024 | SOpen-market sale Common Stock10b5-1 | -661 | $66.96 | $44k | 19,803 | Mar 11, 2024 |
| Mar 10, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -7,345 | $0.00 | $0 | 7,345 | Mar 11, 2024 |
Related signals
Other insiders at Intra-Cellular Therapies, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $8.7M 102,697 shares | -9% | |
| 30Weak | Intra-Cellular Therapies, Inc. | Michael Halstead President | $3.7M 41,583 shares | -182% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $5.1M 70,000 shares | -6% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $7.1M 95,925 shares | -9% | |
| 28Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $9.1M 121,073 shares | -11% | |
| 43Moderate | Intra-Cellular Therapies, Inc. | Mark Neumann EVP, Chief Commercial Officer | $1.4M 18,714 shares | -39% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Rory B Riggs director | $337k 4,462 shares | -4% | |
| 33Weak | Intra-Cellular Therapies, Inc. | Robert L Van Nostrand director | $1.5M 20,000 shares | -67% | |
| 40Moderate | Intra-Cellular Therapies, Inc. | Michael Halstead EVP and General Counsel | $1.4M 20,477 shares | -156% | |
| 47Moderate | Intra-Cellular Therapies, Inc. | Lawrence J. Hineline SVP of Finance, CFO | $1.5M 23,253 shares | -177% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.